• 1
    Cross AH, Naismith RT. Established and novel disease-modifying treatments in multiple sclerosis. J Intern Med 2013; 275: 35568.
  • 2
    Piehl F. A changing MS treatment landscape: challenges and opportunities. J Intern Med 2013; 275: 36986.
  • 3
    Tinghög P1, Hillert J, Kjeldgård L, Wiberg M, Glaser A, Alexanderson K. High prevalence of sickness absence and disability pension among multiple sclerosis patients: a nationwide population-based study. Mult Scler 2013; 19: 192330.
  • 4
    Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 8406.
  • 5
    Sandberg-Wollheim M, Olsson T. Cerebrospinal fluid oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: yes. Mult Scler 2013; 19: 71416.
  • 6
    Henderson AP, Barnett MH, Parratt JD, Prineas JW. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009; 66: 73953.
  • 7
    Stys PK. Pathoetiology of multiple sclerosis: are we barking up the wrong tree? F1000Prime Rep 2013; 5: 20.
  • 8
    Weissert R, Wallstrom E, Storch MK et al. MHC haplotype-dependent regulation of MOG-induced EAE in rats. J Clin Invest 1998; 102: 126573.
  • 9
    Sawcer S, Hellenthal G, Pirinen M et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 21419.
  • 10
    Beecham AH, Patsopoulos NA, Xifara DK et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45: 135360.
  • 11
    Linda H, von Heijne A, Major EO et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009; 361: 10817.
  • 12
    Holmen C, Piehl F, Hillert J et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 2011; 17: 70819.
  • 13
    Sorensen PS, Bertolotto A, Edan G et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18: 14352.
  • 14
    Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009; 73: 696701.
  • 15
    Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Exposure to environmental tobacco smoke is associated with increased risk for multiple sclerosis. Mult Scler 2011; 17: 78893.
  • 16
    Hedstrom AK, Sundqvist E, Baarnhielm M et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 2011; 134: 65364.
  • 17
    Marrie RA, Yu N, Wei Y, Elliott L, Blanchard J. High rates of physician services utilization at least five years before multiple sclerosis diagnosis. Mult Scler 2013; 19: 111319.
  • 18
    Hedström A, Alfredsson L, Lundkvist Ryner M, Fogdell-Hahn A, Hillert J, Olsson T. Mult Scler 2013. [Epub ahead of print].
  • 19
    Hedstrom AK, Olsson T, Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler 2012; 18: 13346.
  • 20
    Hedstrom AK, Akerstedt T, Hillert J, Olsson T, Alfredsson L. Shift work at young age is associated with increased risk for multiple sclerosis. Ann Neurol 2011; 70: 73341.
  • 21
    Sundqvist E, Sundstrom P, Linden M et al. Epstein-Barr virus and multiple sclerosis: interaction with HLA. Genes Immun 2012; 13: 1420.
  • 22
    Khademi M, Kockum I, Andersson ML et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 2011; 17: 33543.
  • 23
    Gunnarsson M, Malmestrom C, Axelsson M et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 839.
  • 24
    Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8: 64756.
  • 25
    Romme CJ, Bornsen L, Ratzer R et al. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS ONE 2013; 8: e57820.